eISSN: 1644-4124
ISSN: 1426-3912
Central European Journal of Immunology
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
2/2024
vol. 49
 
Share:
Share:
abstract:
Clinical immunology

Biomarkers of type 2 and non-type 2 inflammation in asthma exacerbations

Kosar M. Ali
1
,
Nsar Jamal
1
,
Shukur Wasman Smail
2, 3
,
Martin Lauran
4
,
Jonas Bystrom
5
,
Christer Janson
6
,
Kawa Amin
1, 6

  1. Department of Medicine, Microbiology/Immunology, College of Medicine, University of Sulaimani, Iraq
  2. Department of Biology, College of Science, Salahaddin University-Erbil, Kurdistan Region, Iraq
  3. Department of Medical Microbiology, College of Science, Cihan University-Erbil, Kurdistan Region, Iraq
  4. Luton and Dunstable Hospital, Bedfordshire Hospitals NHS Foundation Trust, Luton, UK
  5. Centre for Cancer Cell and Molecular Biology, Barts Cancer Institute, Queen Mary, University of London, London, UK
  6. Department of Medical Science, Respiratory, Allergy and Sleep Research, Uppsala University and University Hospital, Uppsala, Sweden
Cent Eur J Immunol 2024; 49 (2): 203-213
Online publish date: 2024/07/12
View full text Get citation
 
PlumX metrics:
Introduction:
In adult-onset asthma, two major endotypes have been proposed: T2 with eosinophilia and non-T2 characterised by neutrophils and interleukin (IL)-17. The objective of the study was to examine the endotype marker profile in patients with severe asthma who were hospitalized for exacerbations, with a focus on differentiating between viral and non-viral triggers.

Material and methods:
Forty-nine patients with asthma, admitted for exacerbations, and 51 healthy controls (HCs) were recruited. We further categorized the exacerbated asthma patients into two groups: non-viral infected (n = 38) and viral infected (n = 11) groups. Blood was drawn and a nasopharyngeal swab taken at the time of admission and eosinophil numbers, eosinophil cationic protein (ECP), immuno- globulin E (IgE), tryptase and viral infection were determined. Additionally, levels of IL-17, IL-33 and IL-31 were assessed.

Results:
The majority of patients had adult onset asthma (age of diagnosis, 42.8 ±16.1) with a duration of 7.7 ±10.8 years, 24.5% being atopic. Patients had higher levels of eosinophils, ECP and IgE than healthy controls (eosinophils, p = 0.003; ECP and IgE, p = 0.0001). Immunohistochemistry confirmed eosinophils as a source of ECP. Tryptase (p = 0.0001), IL-17 (p = 0.0005), IL-31 (p = 0.0001) and IL-33 (p = 0.0002) were also higher in patients than controls. ECP correlated with tryptase (r = 0.08, p = 0.62). IL-17 showed the best correlation with other mediators, including ECP (r = 0.35, p = 0.24), tryptase (r = 0.69, p = 0.0001), IgE (r = 0.50, p = 0.0001), IL-33 (r = 0.95, p = 0.0001) and IL-31 (r = 0.89, p = 0.0001). IgE, IL-17, and IL-31 had a high AUC when differentiating those with severe and non-severe asthma. The group with exacerbated viral infection showed elevated levels of serum IL-17 and IL-31 compared to the non-infected group.

Conclusions:
Patients with asthmatic exacerbations were found to have higher levels of both T2 and non-T2 inflammatory markers than healthy controls. In the study, levels of IgE, IL-17, and IL-31 differentiated between patients with severe and non-severe asthma. The last two cytokines were also able to distinguish between exacerbated asthma caused by viral infection and exacerbated asthma caused by non-viral infection.

keywords:

asthma, endotype, exacerbation, eosinophils, ECP, IL-17

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.